Neurocrine Biosciences | NBIX - Assets



Neurocrine Biosciences reported $3.54B in Assets for its fiscal quarter ending in September of 2024.

Assets Change Date
AbbVie USD 143.42B 1.48B Sep/2024
Acadia Pharmaceuticals USD 976.87M 62.77M Sep/2024
Agios Pharmaceuticals USD 1.79B 1.02B Sep/2024
ALKERMES USD 2.16B 51.55M Sep/2024
Alnylam Pharmaceuticals USD 4.21B 195.4M Sep/2024
Amgen USD 90.88B 24M Sep/2024
Biogen USD 28.31B 1.51B Sep/2024
BioMarin Pharmaceutical USD 6.85B 215.92M Sep/2024
Cytokinetics USD 1.44B 87.73M Sep/2024
Dynavax Technologies USD 1.06B 45.67M Sep/2024
Exelixis USD 2.96B 187.16M Sep/2024
Gilead Sciences USD 54.53B 946M Sep/2024
Halozyme Therapeutics USD 2.12B 148.58M Sep/2024
Incyte USD 5.01B 350.63M Sep/2024
Intra Cellular Therapies USD 1.32B 3.94M Sep/2024
Ionis Pharmaceuticals USD 3.08B 390M Sep/2024
Neurocrine Biosciences USD 3.54B 230M Sep/2024
Pfizer USD 219.48B 3.28B Sep/2024
Prothena USD 595.25M 50.31M Sep/2024
Regeneron Pharmaceuticals USD 37.44B 1.36B Sep/2024
Repligen USD 2.83B 31.28M Sep/2024
Sarepta Therapeutics USD 3.6B 175.68M Sep/2024
Teva Pharmaceutical Industries USD 41.34B 1.44B Jun/2024
Ultragenyx Pharmaceutical USD 1.54B 80.08M Sep/2024
Vertex Pharmaceuticals USD 22.24B 2.11B Sep/2024